Thus, unbiased identification of DYRK2 as a protein/kinase involved in potential protumorigenic role along with its substrates such as p53, c-Myc, and c-Jun further fuels the need to stratify cancers into subtypes before embarking on DYRK2 molecular studies. This evidence concerns the gene TP53 and cancer.